Hims & Hers Health CFO Oluyemi Okupe sold 36,922 shares in the open market on April 16, 2026 at $25.90 per share, for total proceeds of about $956,150. Because the seller is the company’s chief financial officer, the trade draws attention: CFOs typically have a close view of financial performance, cash flow, and near-term business trends, so investors often track their buying and selling for signals about management’s confidence or personal financial planning. This sale also fits a short-term pattern of insider selling at HIMS. Okupe reported two sales within a few days, including a separate $588,620 sale on April 20, 2026, and another insider, Soleil Boughton, sold about $283,890 on April 20. Multiple sales clustered in time can reflect routine diversification, tax planning, or pre-scheduled selling plans, but it still means insiders as a group were net sellers over the past month. A recent April 9 transfer by CEO Andrew Dudum involved a much larger share count but was described as a non-open-market transfer and not financially significant, making it less directly comparable to cash-generating sales like Okupe’s. Investors typically weigh open-market sales more heavily because they represent an active decision to sell shares for proceeds.